Stockholm, July 5, 2023 – Umecrine Cognition AB today announced that results from a study on a preclinical model of Parkinson’s disease are being presented as a poster at the 6th World Parkinson…
Stockholm, June 7, 2023 – Umecrine Cognition AB today announced new results from a preclinical model of cholestasis that elucidate the mechanism-of-action of the company’s clinical drug candidate…
STOCKHOLM – May 17, 2023. The shareholders in Umecrine Cognition AB, reg. no. 556698-3655, are hereby given notice to attend the annual general meeting at 16:00 on Wednesday 14 June 2023 at…
STOCKHOLM – April 17, 2023. Umecrine Cognition today announces the inclusion of the first patient in a clinical Phase 2 study with its lead compound golexanolone in patients with primary biliary…
STOCKHOLM – March 28, 2023. Umecrine Cognition today announces that the company has secured additional funding of SEK 31,6 million to progress the company´s drug development programs. The…
STOCKHOLM – January 17, 2023. Umecrine Cognition AB today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for the company’s proprietary…
STOCKHOLM – January 9, 2023. Umecrine Cognition today announces that the company will attend the JP Morgan 41st Annual Healthcare Conference in San Francisco, USA. The event takes place 9-12th of…
Stockholm, January 3, 2023 – Umecrine Cognition AB today announced results showing that the company’s clinical drug candidate golexanolone reverses fatigue, anxiety, depression, and some…
Stockholm, September 28, 2022 – Umecrine Cognition AB today announced results showing that the company’s clinical drug candidate golexanolone largely eliminated fatigue in a preclinical disease…
STOCKHOLM – September 14, 2022. Umecrine Cognition today announces that the company has secured funding of SEK 41 million for the start of a Phase 2 study of its drug candidate golexanolone in…